William Blair maintained an Outperform rating on LENZ Therapeutics, Inc. (LENZ) on March 10, 2026. The call reiterates William Blair’s view that VIZZ holds blockbuster potential, and it arrived with a modest intraday pullback of -2.71% ($-0.33).
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
Pre-market GURU.TO stock update Jan 2026: price C$6.76, earnings due 22 Jan. Key margin and guidance signals ahead of TSX report
UNH stock Q4 beat but weaker 2026 guide; Meyka AI explains margin impact, forecasts and price implications
NA9.DE stock at €53.40 on XETRA close 05 Mar 2026 — valuation, technicals and Meyka AI forecast
AVJ.AX stock trades at A$0.66 on ASX with volume 3,012,286 after below‑estimate results. Short-term bounce setup as price holds near 50‑day average; 1
WJ9.SI stock jumps 20.0% pre-market to S$0.006 on 10 Feb 2026 with heavy volume and a 0.01 forecast
RIM.AX stock down 20% pre-market on ASX; Meyka AI flags weak liquidity and a A$0.01 forecast